Due to multiple factors including the Federal Reserve's policy shift and geopolitical sentiment, the Hong Kong stock market has recently shown significant pressure, with major indices experiencing continued volatility and decline. On March 23, 2026, the Hang Seng Index fell below the key 25,000-point level during trading, while the Hang Seng Tech Index also dropped below 4,800 points, with both core indices hitting new lows for the year.
As the Hong Kong market undergoes a broad correction, valuation pressures in its characteristic and advantageous sectors such as technology, pharmaceuticals, and consumer goods have been partially alleviated, potentially making their allocation value increasingly prominent. Market attention on index products like the Huatai-PineBridge Hang Seng Tech ETF (513130), Huatai-PineBridge Hang Seng Biotech ETF (513930), Huatai-PineBridge Hang Seng Consumption ETF (520520), and Huatai-PineBridge Hang Seng Innovative Pharma ETF (520500) has been consistently rising.
Wind data indicates that after three consecutive trading days of cumulative net outflows from all domestic ETFs tracking Hang Seng indices from March 13 to March 17, 2026, the trend successfully reversed from March 18 to March 20. These ETFs recorded net inflows for three consecutive days, with a cumulative net inflow of 2.316 billion yuan during this period. This trend suggests that capital has begun to gradually access high-quality core assets in the Hong Kong market through ETFs, indicating a potentially positive outlook on the market's subsequent recovery.
Regarding investment tools for the Hong Kong market, Huatai-PineBridge Fund offers a comprehensive layout, featuring several high-quality Hang Seng series ETFs. These products cover core sectors of the Hong Kong market, providing investors with convenient and efficient channels for positioning.
Specifically, the Huatai-PineBridge Hang Seng Tech ETF (513130), which includes leading Hong Kong-listed technology companies, has seen its share units increase for four consecutive trading days, surpassing the 80 billion unit mark. The Huatai-PineBridge Hang Seng Consumption ETF (520520) has also attracted capital interest, with its units growing by 78.57% over the last two trading days. Within the Hong Kong pharmaceutical sector, the Huatai-PineBridge Hang Seng Innovative Pharma ETF (520500) focuses precisely on the core innovative drug segment, while the Huatai-PineBridge Hang Seng Biotech ETF (513930) covers both the CXO and innovative drug fields, catering to the diverse needs of different investors.
As one of the market's first ETF managers, Huatai-PineBridge has been dedicated to the index investment field for nearly 20 years, having launched market-first products such as the inaugural dividend-themed ETF and the first cross-market ETF, the Huatai-PineBridge CSI 300 ETF. By the end of 2025, the company's ETFs had generated cumulative profits exceeding 164 billion yuan for holders over the preceding two years, making it one of only four fund companies in the entire market to achieve cumulative profits over one hundred billion during the same period. In terms of fee structure, 77.8% of the company's ETF assets by size adopt the lowest tier fee structure currently available for equity index funds in the market (management fee of 0.15% per annum + custody fee of 0.05% per annum).